Tarsus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering

Frazier Helathcare partners

| Source: Tarsus Pharmaceuticals, Inc

IRVINE, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc., (“Tarsus”) a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities initially in ophthalmic conditions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $88.0 million, before underwriting discounts, commissions, and offering expenses payable by Tarsus. In addition, Tarsus has granted the underwriters an option for a period of 30 days to purchase up to 825,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Tarsus.

Tarsus’ common stock is expected to begin trading on The Nasdaq Global Select Market on October 16, 2020 under the symbol “TARS.” The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

BofA Securities, Jefferies and Raymond James are acting as joint book-running managers for the offering. LifeSci Capital and Ladenburg Thalmann are acting as co-managers for the offering.

A registration statement relating to the offering of these securities was declared effective by the Securities and Exchange Commission (the “SEC”) on October 15, 2020. Copies of the registration statement can be accessed by visiting the SEC website at www.sec.gov. The securities referred to in this release are to be offered only by means of a prospectus. A preliminary prospectus describing the terms of the offering has been filed with the SEC and forms a part of the effective registration statement. When available, a copy of the final prospectus relating to the offering may be obtained from BofA Securities, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC 28255-0001, Attn: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; Jefferies at 1-877-821-7388 or by email at prospectus_department@jefferies.com; and Raymond James at 1-800-248-8863 or by email at prospectus@raymondjames.com.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Forward-Looking Statements

Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” These statements include, but are not limited to, statements relating to the expected trading commencement and closing dates. The words, without limitation, “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms of the offering or at all, and other factors discussed in the “Risk Factors” section of the preliminary prospectus that forms a part of the effective registration statement filed with the SEC. Any forward-looking statements contained in this press release are based on the current expectations of Tarsus’ management team and speak only as of the date hereof, and Tarsus specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media Contact:
Allison Howell
Pascale Communications, LLC
allison@pascalecommunications.com

Categories: News

Tags:

Eurazeo Patrimoine supports C2S GROUP’S expansion with the acquisition of four new clinics

Eurazeo

Paris, 12 October 2020
Eurazeo Patrimoine, the Eurazeo division specialising in real estate and in companies operating their own real assets, has been an investor in C2S Group since March 2018. Currently the eighth-largest operator of private clinics in France, C2S Group today announced that it has stepped up its expansion with the acquisition of four additional clinics in Franche-Comté: the Clinique Saint-Vincent and the Polyclinique de Franche-Comté in Besançon, the Clinique Saint-Pierre in Pontarlier, and the Polyclinique du Parc in Dole.

The integration of these four clinics, all leading facilities in their catchment areas, staffed by teams of recognised professionals and offering complete diagnostic and treatment services, will allow C2S Group to build up a first-rate network of clinics in Franche-Comté.

Since the acquisition of C2S in 2018, Eurazeo Patrimoine has lent its support to the Group as an active shareholder, bringing it the human and financial resources necessary for its growth, thus contributing to a twofold increase in activity in just three years, accompanied by the expansion of its network in south-east central and eastern France. The integration of five new clinics in Auxerre, Vesoul, Grenoble, Dole and Pontarlier, together with two in Besançon, all acquired over a period of less than three years, alongside the 11 facilities already being managed by C2S in 2018 when it was acquired by Eurazeo Patrimoine, has enabled the Group to increase its footprint, bringing it closer to patients and making it the leading operator of multidisciplinary clinics in the Auvergne-Rhône-Alpes and Bourgogne-Franche-Comté regions.

Thanks to the strategic vision shared by the senior executives of both C2S and Eurazeo Patrimoine, the Group has also been able to better align its business model with its values of closeness, quality, balanced medical and managerial governance, and responsible development during this growth phase.
Lastly, Eurazeo Patrimoine’s support for C2S Group has been reflected in major investment programmes: in real estate (expansion and renovation projects, creation of surgical units as well as new out-patient or emergency services) to modernise its clinics and accompany the rise in activity; in medical equipment (acquisition of surgical robots, including the first European CMR robot in operation in France) to provide the facilities and their practitioners with state-of-the-art tools and ensure an excellent standard of care for patients within their communities; and in digital technology, including the digitisation of the patient experience and a strengthened partnership with Doctolib, of which Eurazeo is a main shareholder.

Renaud Haberkorn, Head of Eurazeo Patrimoine, said:
We are very pleased to have supported C2S for nearly three years. With its recent acquisitions, the Group has taken a major step forward in its growth and in the consolidation of its leadership position in its sector at the regional level. Since 2018, Eurazeo Patrimoine’s teams have worked very closely with those at C2S Group. We are proud to be accompanying this preeminent healthcare provider in the Auvergne-Rhône-Alpes and Bourgogne-Franche-Comté regions through every step of its development.

Jean Rigondet, Chairman of C2S Group, said:
The four recently acquired clinics are all leading healthcare facilities for the Franche-Comté area, staffed by teams of talented professionals, working in a coordinated manner and with a collegial spirit, able to offer a full care pathway to patients. We are pleased that these clinics are joining the Group and that we are able to ensure a high standard of care for their communities. We aim to meet the needs of patients by providing them with top-quality healthcare services across a range of disciplines. In line with C2S Group’s continuing growth, our partnership with our shareholder Eurazeo Patrimoine, and the relationship based on attentiveness and mutual trust that we enjoy, are essential to the Group’s development.

About Eurazeo
• Eurazeo is a leading global investment company, with a diversified portfolio of €18.5 billion in assets under management, including €12.9 billion from third parties, invested in over 430 companies. With its considerable private equity, real estate and private debt expertise, Eurazeo accompanies companies of all sizes, supporting their development through the commitment of its nearly 300 professionals and by offering in-depth sector expertise, a gateway to global markets, and a responsible and stable foothold for transformational growth. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term.

• Eurazeo has offices in Paris, New York, São Paulo, Seoul, Shanghai, London, Luxembourg, Frankfurt, Berlin and Madrid.
• Eurazeo is listed on Euronext Paris.
• ISIN: FR0000121121 – Bloomberg: RF FP – Reuters: EURA.PA

EURAZEO CONTACTS

PIERRE BERNARDIN
HEAD OF INVESTOR RELATIONS
Email: pbernardin@eurazeo.com
Tel: +33 (0)1 44 15 16 76

VIRGINIE CHRISTNACHT
HEAD OF COMMUNICATIONS
Email: vchristnacht@eurazeo.com
Tel: +33( 1 44 15 76 44

 

PRESS CONTACT

MAITLAND/amo
DAVID STURKEN
Email: dsturken@maitland .co .uk
Tel: +44 ( 7990 595 913

 

Categories: News

Tags:

Miura invests in the healthcare sector by partnering with Terrats Medical

Miura Capital

Terrats Medical is a leading global company in dental implant and abutments production and solutions, operating under DESS Dental Smart Solutions
• Miura joins forces with the management team to boost international growth in global markets

Miura Private Equity, a Spanish leading investment firm, has closed an investment agreement with Terrats Medical, a major global company in design and production of dental implants and abutments that operates under DESS Dental Smart Solutions brand. Miura will support the management team in their consolidation and international growth plan.

Terrats Medical is family owned business with more than 70 years of history currently led by the third generation and headquartered at Barcelona. The company is one of the best players in high tech abutments, dental implant related products and medical devices as well as engineering, production and certification of their products, with a strong presence in international markets such as the US, Europe (Germany, France and the Nordic countries) and Asia, thanks to a wide network of partners in distribution, research centers and dental clinics. DESS is present nowadays in more than 35 countries and sells abroad more than 90% of its total revenue.

The company uses state of the art technology to design and manufacture world-class implant abutments and dental implants. In addition, Terrats Medical provides tailored OEM (Original Equipment Manufacturer) and private label services to other dental implant brands.
According to Luis Seguí, CEO & Founding Partner at Miura, “It is a strategic investment in the Healthcare sector in which we can provide value and know-how on family businesses and help the company reach new global heights.”

Carlos Julià, Miura’s deal leading partner said: “We are very excited to join forces with Terrats family. We will work side by side with the management team to keep on growing on global markets thanks to Terrats Medical vision and performance, as well as our expertise on developing family businesses based on industrial sectors with a strong international focus.”

Roger Terrats, CEO of Terrats Medical, concluded that: “The partnership with Miura sets a news stage of growth and consolidation that will reinforce our position as high-end medical and dental company. In addition, they provide stability and a higher magnitude to our business, which has been ongoing for the last 70 years thanks to our committed entrepreneurship, responsibility, and customer care. Values that Miura endorses altogether.”
The transaction was advised by PwC, KPMG and Gómez-Acebo y Pombo.

About Miura
Miura is a leading investment firm in Spain with assets under management totaling more than €1 billion through its Private Equity and Agribusiness funds. The firm specializes in investing in Spanish family businesses with attractive growth and consolidation plans, and with a clear international vocation. Since the year 2008, Miura has invested in more than 40 companies, with transactions valued in more than €1,5 billion.
Find more: www.miuraequity.com

About Terrats Medical and DESS Dental Smart Solutions
Terrats Medical is a major global company in design and production of dental implant and abutments that operates under DESS Dental Smart Solutions brand. DESS is present nowadays in more than 35 countries and sells abroad more than 90% of its total revenue. Since 2009 Terrats Medical has transformed its core business from a specialist contract manufacturing of small metalic precision components to a global company in the dental implant dentistry.
Find more: www.dess-abutments.com

Categories: News

Tags:

ProductLife Group further strengthens its pharmacovigilance offering with the acquisition of Axpharma

October 6, 2020

This strategic acquisition, the first since 21 Invest took a majority stake in ProductLife Group in 2019 and appointed new CEO Xavier Duburcq, is part of the Group’s aim to widen its expertise and global reach.

ProductLife Group (PLG), a specialist provider of regulatory and compliance services for the life sciences industry, acquires Axpharma from Galiena Capital and refinances its debt alongside securing the means to achieve the next steps of its ambitious buy-and-build strategy.

Founded in 2001 by Florence Postel and accompanied by Galiena Capital as majority shareholder since 2015, Axpharma is a prominent pharmacovigilance service provider in Europe. Its team of experts enjoys a strong reputation for providing highly dependable services in the areas of case management, medical writing, medical literature monitoring, pharmacovigilance responsibility delegation, and around-the-clock medical information. Its clients include pharmaceutical, biopharmaceutical, medical device and cosmetics companies, primarily in Europe.

This acquisition falls perfectly in line with PLG’s growth acceleration and transformation plan. It will support the Group’s ambition to become the leading global provider of regulatory and compliance services in life sciences, covering regulatory affairs, clinical safety, pharmacovigilance, and quality. Pharmacovigilance services, in particular, are currently facing strong and growing international demand from life sciences companies, and PLG’s capabilities in the field will be strongly bolstered via the Axpharma deal.

ProductLife Group is ideally positioned to capitalise on this opportunity thanks to its global full-service contract model (on-shore and off-shore resourcing), its strategic use of smart technology and its best-in-class institutional team, recently reinforced with the appointment of Candice Bosson as group vice-president of human resources & talent management, and of Paolo Guerra, as new medical device lead.

Commenting on the Axpharma acquisition, PLG CEO Xavier Duburcq said, “Our strategic priority is to reinforce PLG’s ability to address the needs of today’s biopharma and medical product industry, drawing upon decades of experience in management of scientific and regulatory aspects of medicine. The merger of PLG and Axpharma offers tremendous potential to further invest in automation and artificial intelligence, as part of the aim to offer to our clients reliable, innovative, and cost-effective solutions that are always one step ahead of what the industry expects.

“I have known Axpharma for some years, and our positive work cultures make a great match. Working with the company’s well-respected and similarly-motivated team will bring exciting opportunities for us all. This acquisition also includes Audithem, an emerging company providing auditing services in pharmaceutical good practices, which will support PLG’s ambition to grow in the Quality and Compliance area,” he continued.

Speaking for both Axpharma and Audithem, Managing Director Sophie Brisset-Jaillet, said, “We are delighted at this meeting of minds and goals and we’re excited at the prospect of being part of PLG, a larger group with an excellent reputation and a broader reach. Together there is so much more we can do which can only benefit our clients and our employees. This is an exciting step for our companies. Our teams will now be able to work together in a fluid and efficient manner so that we can continue the good work we do making it even better and stronger.”

Fabrice Voituron, Managing Partner at 21 Invest, said, “The strengthening of ProductLife Group’s organization together with its good commercial momentum today result in the acceleration of the buy-and-build strategy, in spite of the context. Indeed, the Axpharma opportunity embodies the start of a new phase of growth, demonstrating PLG’s willingness to widen its expertise and expand its geographical reach notably in the United States and Europe. Supported by a new acquisition financing line, the Group has the means to support its ambitions and is expected to make further announcements in the next few months.”

Although ProductLife Group, in common with its peers around the world, must manage its plans within the constraints of the continuing pandemic, the organisation has identified strong growth markets and maintained strong performance, as demand for its services has remained buoyant. Indeed, the organisation has seen significant commercial successes in 2020, including some notable COVID-19 safety projects and a significant deal to manage the regulatory and quality activities of a large generic-drug organisation.

Categories: News

Tags:

Metlifecare securityholders vote in favour of APVG acquisition

No Comments

eqt

Metlifecare (NZX: MET, ASX: MEQ) announced its securityholders have overwhelmingly approved the acquisition of Metlifecare by APVG, an entity owned by EQT Infrastructure IV, at the Scheme Meeting held in Auckland, New Zealand today.

EQT is pleased to confirm that the resolution to approve the Scheme was passed by a significant majority of shareholders, with more than 90 percent of shares voted in favour of the transaction.

Metlifecare is a leading New Zealand owner and operator of retirement villages, providing rewarding lifestyles and outstanding care to more than 5,600 New Zealanders. Established in 1984, it currently owns and operates a portfolio of 25 villages in areas with strong local economies, supportive demographics and high median house prices, located predominantly in New Zealand’s upper North Island.

EQT is a differentiated global investment organization that invests in good companies across the world with a mission to help them develop into great and sustainable companies. By providing access to ownership skills and operational expertise, EQT helps acquired companies grow and prosper. Development and growth are at the core of the value creation, with digitalization and sustainability being key future-proofing drivers. Portfolio companies owned by the funds of EQT have, on average, increased sales by 10 percent, the number of employees by 7 percent and EBITDA by 12 percent per annum during the funds’ ownership.

Ken Wong, Managing Director, Head of EQT Australia & New Zealand and Investment Advisor to EQT Infrastructure IV, said: “We welcome the decision today by Metlifecare’s shareholders to support the proposed transaction and vote overwhelmingly in favour of the scheme of arrangement. EQT looks forward to applying its long-term vision to accelerate Metlifecare’s growth and deliver the highest quality care to its residents. I would also like to extend my appreciation and thanks on behalf of EQT to Metlifecare’s employees who have worked tirelessly during this period to protect the health and wellbeing of its residents during an unprecedented year.”

The closing of the transaction is subject to court approval. It is currently contemplated that the Scheme will be implemented in late October 2020.

APVG and EQT Infrastructure IV are being advised by Goldman Sachs, Bell Gully, King & Wood Mallesons, Simpson Thacher & Bartlett, EY and Colliers.

Contact
International media inquiries: EQT Press Office, press@eqtpartners.com
New Zealand media inquiries: David Lewis, david@thompsonlewis.co.nz, +64 21 976 119
Australian media inquiries: Jim Kelly, jim@domestiqueconsulting.com.au, +61 412 549 083

About EQT
EQT is a differentiated global investment organization
with more than EUR 62 billion in raised capital and around EUR 40 billion in assets under management across 19 active funds. EQT funds have portfolio companies in Europe, Asia-Pacific and North America with total sales of more than EUR 27 billion and approximately 159,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership.

More info: www.eqtgroup.com
Follow EQT on
LinkedIn, Twitter, YouTube and Instagram

About Metlifecare
Metlifecare is a leading New Zealand owner and operator of retirement villages, providing rewarding lifestyles and outstanding care to more than 5,600 New Zealanders. Established in 1984, it currently owns and operates a portfolio of 25 villages in areas with strong local economies, supportive demographics and high median house prices, located predominantly in New Zealand’s upper North Island.

More info: www.metlifecare.co.nz

Categories: News

Tags:

Gimv invests in French company Biolam for further roll-out as regional challenger in medical diagnostics laboratories

GIMV

Gimv supported Daniel Attias’ MBI takeover of the Biolam group of laboratories in Amiens, with the ambition to set up a network of reference medical diagnostics laboratories in the north-western region of France. The group is now entering a new phase with the acquisition of Biocéane, a leading player in the Le Havre area.

The adventure began in December 2019 with the acquisition of a platform of 3 laboratories in Amiens and aimed to combine two growth strategies: the opening of laboratories in areas with a shortage of supply and the conduct of external growth operations. Building on the success at Biolab, which was sold to Eurofins in 2018, Daniel Attias is investing heavily in this new project.

Nine months later, the Biolam group (www.groupebiolam.fr) has already opened 4 laboratories in the Hauts-de-France region, acquired the Gilbert-Bourgois laboratory in Douai and announced the acquisition of the Biocéane group, a leading player in the Le Havre area. As part of the latest operation announced this morning, its founder Didier Thibaud, attracted by the entrepreneurial project proposed, joined forces with the Biolam group, which now has 15 laboratories and 150 employees, and generates a turnover of around 20 million euros in the Hauts-de-France and Normandy. Several growth projects are currently being studied.

Gautier Lefebvre, Partner at Gimv, and Kevin Klein, Principal at Gimv, declare: “We are delighted to support Daniel Attias and Didier Thibaud with this exciting and relevant healthcare project. This operation fits perfectly with the philosophy of our Health & Care platform. We will do our utmost to actively empower the group in its further development.” 

Daniel Attias, President of the Biolam group, says: “The selection of Gimv as partner for the Biolam project was self-evident, because of their knowledge of the healthcare sector and their ability to support a very fast build-up strategy. Our growth in this special year already shows that our tandem is working perfectly, offering promising prospects for the coming years.”

With this new investment, Gimv’s Health & Care team continues to focus on European consolidation projects, alongside ambitious management teams.

Categories: News

Tags:

TFS enters partnership in the US with the Duke Clinical Research Institute

Ratos

2020-09-29

TFS has entered into a strategic partnership with the Duke Clinical Research Institute (DCRI) in North Carolina, US, to provide data management solutions in clinical trials.

The unique collaboration expands TFS’s capability to execute clinical trials for both commercial and government sponsors in the U.S. It supports the company’s growth strategy and further develops its scientific offering. Duke Clinical Research Institute is a world-renowned research institute, recognized for bringing innovation to clinical trial design and execution.

“DCRI is known for ushering in new and innovative approaches to clinical research, and TFS is a leader in providing quality clinical development services through operational excellence and a customer-centric approach. TFS data management solutions ensure quality data services while it continues to push boundaries in study design and management as part of our shared mission to serve patients throughout the world,” says Bassem Saleh, TFS Chief Executive Officer.

“The partnership with Duke Clinical Research Institute is a strategic step toward expanding TFS’ service offering in North America and it opens up doors for further collaboration. TFS provides tailored solutions and is well-positioned to manage complex global studies. The recent agreement strengthens our US presence, while leveraging the European capabilities,” says Joakim Twetman, Head of Business Area Industry at Ratos.

For further information, please contact:
Joakim Twetman, Head of Business Area Industry, Ratos, +46 8 700 17 00
Helene Gustafsson, Head of IR and Press, Ratos, +46 8 700 17 98, helene.gustafsson@ratos.se

About TFS:
TFS is a global, mid-sized, clinical contract research organisation (CRO) that supports biotech companies through the entire clinical development process. TFS focuses its scientific and medical competence across a broad therapeutic spectrum, with industry-leading capabilities in dermatology, oncology and ophthalmology. TFS has two business Areas: Clinical Development Services (CDS), which offers clinical trials for small pharmaceutical companies during the development process, and Strategic Resourcing Solutions (SRS), which offers resource solutions featuring clinical professionals and targeting major pharmaceutical companies. Over the past five years, TFS has been involved in approximately 1,100 studies in 40 countries across Europe and North America.

About Ratos:
Ratos is a business group consisting of 12 companies divided into three business areas: Construction & Services, Consumer & Technology and Industry. In total, the companies have SEK 38 billion in sales and EBITA of SEK 1.8 billion. Our business concept is to develop mid-sized companies headquartered in the Nordics that are or can become market leaders. We enable independent mid-sized companies to excel by being part of something larger. People, leadership, culture and values are key focus areas for Ratos. Everything we do is based on Ratos’s core values: Simplicity, Speed in Execution and It’s All About People.

Within3 Raises over $100 Million in Growth Funding to Fuel Rapid Global Expansion

Life science companies worldwide are using Within3 as their primary platform for enterprise-wide virtual communication

Within3, the leading enterprise-wide solution for life science collaboration and communication, closed over $100 million in growth funding in a financing round led by Insight Partners, with participation from Silversmith Capital Partners. The funding will be used to accelerate product innovation, build infrastructure to outpace growing demand, and fuel international expansion.

20 out of the top 20 pharmaceutical companies already use Within3 for global collaboration to bring drugs to market more quickly, publish clinical studies, host advisory boards and engage virtually on any business initiative with multi-stakeholder involvement. With users in over 150 countries and thousands of implementations worldwide, Within3 is the pioneer in enabling complex virtual communication in a secure environment. Each implementation is carefully designed to drive business outcomes and allows asynchronous participation supplemented with real-time touchpoints. Always-available reporting and analytics ensure real-time alignment of program goals. Within3’s unique combination of real-time and over-time communication drive the highest level of engagement and strong, measurable business results across the enterprise.

“Global demand for our solution is surging at an unprecedented rate,” said Lance Hill, CEO of Within3. “Life science companies are looking for virtual work solutions that exceed the level of engagement of traditional live interactions, meet all their compliance needs, and that will scale across the enterprise. They have found that solution with Within3.”

“The funding will allow us to accelerate our growth and product pipeline to continue to meet the growing demand from the market,” continued Hill. “We will be able to accelerate new innovations in our product roadmap and bring our customers smarter, more innovative solutions faster.”

“Investment opportunities in companies like Within3 don’t come around very often,” said Deven Parekh, Managing Director at Insight Partners. “The company has seen explosive growth over the last 12 quarters and continues to break new records each month. Their unparalleled ability to enable companies to achieve the results they desire faster and cheaper, and scale across the enterprise solving complex problems in all divisions of an organization sets them apart from other virtual engagement solutions. At a time when collaboration, communication and cooperation are more critical than ever across the global life sciences ecosystem, we are excited to bring our strategic operations expertise to help Within3 scale.” Parekh, along with Insight Partners’ Managing Directors Adam Berger and Ross Devor will join Within3’s board.

With over 80 compliance features, translation into more than 100 languages and a world-class client success team that is a part of every single implementation, life science companies are turning to Within3 as an enterprise-wide solution and their primary resource for stakeholder engagement.

Aeris Partners LLC served as the exclusive financial advisor to Within3. Willkie Farr & Gallagher served as legal advisors to Insight, and Kirkland and Ellis represented Silversmith Capital Partners.

ABOUT WITHIN3

Within3 invented a better way for life sciences companies to have conversations with the people who matter most—from doctors to patients to payers, and more. Our virtual engagement platform gives stakeholders the freedom to communicate anytime, anywhere, on any device. With practical tools to foster meaningful discussions and a dedicated client success team on every project, most Within3projects achieve 100% stakeholder participation. Learn more at www.within3.com or follow us on Twitter @Within3.

ABOUT INSIGHT PARTNERS

Insight Partners is a leading global venture capital and private equity firm investing in high-growth technology and software ScaleUp companies that are driving transformative change in their industries. Founded in 1995, Insight Partners has invested in more than 400 companies worldwide and has raised through a series of funds more than $30 billion in capital commitments. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with practical, hands-on software expertise to foster long-term success. Across its people and its portfolio, Insight encourages a culture around a belief that ScaleUp companies and growth create opportunity for all. For more information on Insight and all its investments, visit www.insightpartners.com or follow us on Twitter @insightpartners.

ABOUT SILVERSMITH CAPITAL PARTNERS

Founded in 2015, Silversmith Capital Partners is a Boston-based growth equity firm with $1.1 billion of capital under management. Silversmith’s mission is to partner with and support the best entrepreneurs in growing, profitable technology and healthcare companies. The partners have over 75 years of collective investing experience and have served on the boards of numerous successful growth companies.

Contacts

Whitney Hausmann
whausmann@within3.com

Related Information

View Here

CDPQ co-invests with EQT in Colisée, a European leader in elderly care

Cdpq

nfrastructure Montréal,

share

 
CDPQ’s investment alongside EQT Infrastructure V (EQT Infrastructure, majority shareholder) and Colisée’s management team will enable the company to consider new growth opportunities, including in new markets, while consolidating its high-quality care and services offering.Headquartered in Paris, Colisée currently operates more than 270 nursing home facilities as well as home care services agencies, mainly in France, Belgium, Spain and Italy. In addition to nursing home facilities, Colisée has diversified its offering to provide more services to help the elderly. The company employs more than 16,000 people and has annual revenues of over €1 billion.

This stake is the culmination of talks with Colisée management that began in 2019 and is part of CDPQ’s enhanced infrastructure investment strategy in Europe. As a long-term investor, CDPQ will support Colisée in its development plan, which takes into account major trends such as the aging population and growing demand for elder care services.

“For CDPQ, this acquisition represents a significant investment in health care infrastructure, an essential sector where needs are growing and where Colisée is well positioned,” said Emmanuel Jaclot, Executive Vice-President and Head of Infrastructure at CDPQ. “Colisée’s excellent track record in terms of quality of care and resident well-being is a crucial element of this partnership, and is consistent with our ESG approach.”

“With the support of a long-term investor like CDPQ, Colisée will continue developing its elder care services. CDPQ shares common values with our company, and social responsibility is at the heart of its mission,” stated Christine Jeandel, President of Colisée.

“EQT Infrastructure is proud to have the participation of a high-quality partner such as CDPQ for this investment in social infrastructure, a thematic investment for EQT. With CDPQ’s investment alongside EQT Infrastructure, Colisée will benefit from shareholders who can support the group’s strong growth over the long term, said Ulrich Köllensperger, Partner and Thomas Rajzbaum, Managing Director at EQT Partners and investment advisors at EQT Infrastructure.

The transaction is subject to regulatory approvals. The financial terms of the transaction were not disclosed.

ABOUT CAISSE DE DÉPÔT ET PLACEMENT DU QUÉBEC

Caisse de dépôt et placement du Québec (CDPQ) is a long-term institutional investor that manages funds primarily for public and parapublic pension and insurance plans. As at June 30, 2020, it held CA$333.0 billion in net assets. As one of Canada’s leading institutional fund managers, CDPQ invests globally in major financial markets, private equity, infrastructure, real estate and private debt. For more information, visit cdpq.com, follow us on Twitter @LaCDPQ or consult our Facebook or LinkedIn pages.

ABOUT COLISÉE

Colisée is a key player in the global health care and old-age dependency sector, and has developed a real expertise in elderly people care and well-being. Its network includes 270 facilities in France, Belgium, Spain and Italy. Colisée employs more than 16,000 people. For more information: www.groupecolisee.com.

ABOUT EQT

EQT is a differentiated global investment organization with more than EUR 62 billion in raised capital and around EUR 40 billion in assets under management across 19 active funds. EQT funds have portfolio companies in Europe, Asia Pacific and North America with total sales of more than EUR 27 billion and approximately 159,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. For more information: www.eqtgroup.com. Follow EQT on LinkedIn, Twitter, YouTube and Instagram.

Categories: News

Tags:

BGF welcomes successful exit of Brindley Healthcare

BGF

BGF has welcomed the successful acquisition of a 50% shareholding in Brindley Healthcare by French multinational Orpea, a leading European operator in dependency care.  As a result of the transaction, BGF has now exited the business which was its first investment in the Republic of Ireland.

Speaking today, Leo Casey, Head of BGF in Ireland, wished Brindley Healthcare and Orpea every success in the future; “Brindley was our first investment in Ireland and we are immensely proud of it.  Brindley is now one of the largest nursing home groups in the country.  We were delighted to be able to support Amanda Torrens and her team on their ambitious growth agenda over the past two years.  Typically, our investments are for longer terms than is the case in this instance but in BGF we also don’t stand in the way of our investee companies when the right exit comes around.  In Orpea, Brindley have attracted a highly credible international operator that will underpin their leadership position in the Irish market.”

Amanda Torrens, founder and CEO of Brindley Healthcare paid tribute to BGF and the support they provided to the business; “I can’t speak highly enough of BGF.  Their support for the business over the past two years enabled us to grow strongly and make two acquisitions.  At every stage BGF were supportive and enthusiastic for our plans and I particularly want to acknowledge the generous manner in which they encouraged us to explore this opportunity with Orpea.”

BGF began working with Brindley Healthcare in 2018 and announced its investment in the company at the start of January 2019.  BGF invested €10 million at that time which was used to finance a number of strategic acquisitions and expand the management team.  With BGF’s support, Brindley grew from a network of 8 nursing homes with 400 beds to its current position of 10 nursing homes with a total of 600 beds.

Over the past two years, BGF has made four further investments in businesses in the Republic of Ireland since the investment in Brindley Healthcare.

Categories: News

Tags: